Palvella Therapeutics (PVLA) Cash from Financing Activities (2016 - 2024)
Historic Cash from Financing Activities for Palvella Therapeutics (PVLA) over the last 12 years, with Q4 2024 value amounting to $74.8 million.
- Palvella Therapeutics' Cash from Financing Activities rose 60595.36% to $74.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $87.1 million, marking a year-over-year increase of 164178.0%. This contributed to the annual value of $87.1 million for FY2024, which is 164178.0% up from last year.
- Per Palvella Therapeutics' latest filing, its Cash from Financing Activities stood at $74.8 million for Q4 2024, which was up 60595.36% from $2.4 million recorded in Q3 2024.
- Palvella Therapeutics' 5-year Cash from Financing Activities high stood at $74.8 million for Q4 2024, and its period low was -$14.8 million during Q4 2023.
- In the last 5 years, Palvella Therapeutics' Cash from Financing Activities had a median value of $5.7 million in 2021 and averaged $10.5 million.
- Over the last 5 years, Palvella Therapeutics' Cash from Financing Activities had its largest YoY gain of 693950.18% in 2023, and its largest YoY loss of 1599354.84% in 2023.
- Quarter analysis of 5 years shows Palvella Therapeutics' Cash from Financing Activities stood at $75000.0 in 2020, then surged by 6434.67% to $4.9 million in 2021, then plummeted by 98.1% to $93000.0 in 2022, then tumbled by 15993.55% to -$14.8 million in 2023, then surged by 605.95% to $74.8 million in 2024.
- Its last three reported values are $74.8 million in Q4 2024, $2.4 million for Q3 2024, and $9.9 million during Q2 2024.